Company Overview of Flagship Ventures
Flagship Ventures is a private equity and venture capital firm specializing in incubation, seed stage, early, later and growth stage investments. The firm prefers to invest in the healthcare including biotherapeutics, life sciences, medical technologies, and biological discoveries leading to new therapies, advanced analysis for improved medicine, chemistries and small molecule drugs, nanotechnology for medicine; energy efficiency; bioenergy; sustainability, focusing on energy, water, and agriculture/nutrition; and clean technology sector. The firm seeks to invest in Midwest, focusing on investing nationally. It seeks to initially invest between $500,000 and $5 million, with a typical investm...
One Memorial Drive
Cambridge, MA 02142
Founded in 2000
Key Executives for Flagship Ventures
Co-Founder, Senior Managing Partner, and Chief Executive Officer
Co-Founder and Managing Partner
Chief Financial Officer and Controller
Chief Operating Officer, Partner, and General Partner
Partner and Chief Business Officer
Compensation as of Fiscal Year 2015.
Flagship Ventures Key Developments
Flagship Ventures Launches Evelo Therapeutics to Develop Microbiome Therapies for Cancer
Nov 4 15
Flagship Ventures announced it has launched Evelo Therapeutics, a new company focused on leveraging the power of the microbiome to develop novel therapies for cancer, with an initial capital commitment of $35 million. Evelo is pioneering Oncobiotic therapeutics, a new modality in cancer therapy based on the cancer microbiome. Evelo is the first company to systematically identify, characterize and understand the biology of cancer-associated bacteria (CAB) and bacterial immune activators (BIAs), providing new insights into cancer metabolism and immuno-oncology. Evelo's Oncobiotic platform would treat cancer through unprecedented therapeutic modalities. Evelo's novel approaches leverage tumor-microenvironment modifications that can be mediated by the microbiome to disrupt tumor metabolism and the interactions between the tumor and surrounding tissue. Evelo is also exploring novel Oncobiotic approaches that can leverage the ability of bacteria to uniquely and powerfully activate the immune system to fight cancer. In this respect, Evelo is developing a next-generation approach to immuno-oncology that goes beyond check-point inhibitors and CAR-T cell therapies.
Flagship Ventures Presents at BIO-Europe 2015, Nov-02-2015 04:00 PM
Oct 1 15
Flagship Ventures Presents at BIO-Europe 2015, Nov-02-2015 04:00 PM. Venue: Munich, Germany. Speakers: Jeremy Springhorn, Partner, Corporate Development.
Flagship Ventures Presents at BioPharm America 2015, Sep-15-2015 09:00 AM
Sep 12 15
Flagship Ventures Presents at BioPharm America 2015, Sep-15-2015 09:00 AM. Venue: Boston Marriott Copley Place, 110 Huntington Avenue, Boston, MA 02116, United States. Speakers: Geoffrey von Maltzahn, VentureLabs Partner.
Similar Private Companies By Industry
Recent Private Companies Transactions